Genome sequencing identified diagnoses in 15% of individuals with unsolved developmental and epileptic encephalopathies.
This cohort study evaluated 242 individuals with unsolved developmental and epileptic encephalopathies (DEEs) who had previously tested negative on genetic testing. The population consisted of patients with unsolved cases where standard exome or gene panel analysis had failed to identify a cause.
The intervention involved performing genome sequencing along with enhanced variant analyses outside of coding regions. This approach was compared against the baseline of prior genetic testing, which included exome or gene panel analysis. The primary outcome measured was the achievement of a molecular diagnosis.
Results showed that 36 of 242 participants, or 15%, received a molecular diagnosis through this enhanced genomic approach. The absolute diagnostic yield was 15% when comparing the new sequencing strategy to the prior testing methods. No specific adverse events, serious adverse events, discontinuations, or tolerability data were reported in the study.
The study design was observational, and the findings reflect associations rather than causal effects. Limitations regarding the generalizability of these results to other clinical settings or populations were not detailed in the provided data. The certainty of these findings is constrained by the observational nature of the cohort design and the specific context of unsolved DEEs.